一種紫杉醇洗脫的冠狀動(dòng)脈支架系統(tǒng)整合了下一代支架技術(shù)，具有高度靈活的細(xì)胞幾何學(xué)、超薄支柱以及均勻一致的細(xì)胞分布。

這種支架叫做Taxus Liberte，是波士頓科學(xué)公司的產(chǎn)品，擁有Veriflex設(shè)計(jì)的特性。這種新型平臺(tái)為戰(zhàn)勝解剖學(xué)難題提供了更好的輸送放置特性和一致性。它還同時(shí)具有增強(qiáng)TrakTip導(dǎo)管尖端放置在輸送導(dǎo)管上，這樣提供了更好的穿越病變區(qū)域的功能。除此之外，TrakTip需要穿越的病變區(qū)域較小，這也增強(qiáng)了穿越功能。Taxus Liberte現(xiàn)在已經(jīng)在全球18個(gè)國(guó)家上市。

Mercy醫(yī)院和Auckland城市醫(yī)院介入心血管醫(yī)師John Ormiston醫(yī)生評(píng)論說(shuō)：“我個(gè)人使用Liberte系統(tǒng)的經(jīng)驗(yàn)證實(shí)該產(chǎn)品是支架工藝所取得的一個(gè)巨大進(jìn)步。它適應(yīng)血管壁的能力是無(wú)與倫比的，而且它易于輸送放置的特性使得醫(yī)生更加容易的到達(dá)一些很難觸及的病變區(qū)域。”

為了得到美國(guó)食品藥品管理局對(duì)這種支架系統(tǒng)的批準(zhǔn)，波士頓科學(xué)公司已經(jīng)宣布開始臨床試驗(yàn)。公司第一代藥物洗脫支架系統(tǒng)，Taxus Express2紫杉醇洗脫冠狀動(dòng)脈支架系統(tǒng)，是世界上冠狀動(dòng)脈支架市場(chǎng)首屈一指的產(chǎn)品。
 
Paclitaxel-Eluting Coronary Stent
 
A paclitaxel-eluting coronary stent system incorporates a next-generation stent with highly flexible cell geometry, thin struts, and uniform cell distribution.

Called Taxus Liberte, the stent is the product of Boston Scientific corp. (Natick, MA, USA) and features the Veriflex design. This new platform offers better delivery and conformity in challenging anatomy. It also features the enhanced TrakTip catheter tip, mounted on the delivery catheter, which provides better lesion crossability. In addition, TrakTip has a low lesion-entry profile, which further improves crossability. The Taxus Liberte is now being marketed in 18 countries around the world.

“My experience with the Liberte system demonstrates that it represents a dramatic step forward in stent technology,” commented John Ormiston, M.D., interventional cardiologist at Mercy Hospital and Auckland City Hospital (New Zealand). “Its ability to conform to the vessel wall is outstanding, and its ease of deliverability allows us to more easily reach some of the difficult lesions.”

Boston Scientific has announced enrollment in a clinical trial designed to support approval of the stent system by the U.S. Food and Drug Administration (FDA). The company’s first-generation drug-eluting stent system, the Taxus Express2 paclitaxel-eluting coronary stent system, is the leader of the worldwide coronary stent market.